A Phase 1b Multicenter Open-Label Safety Tolerability and

Recruiting

99 years or below

All

Phase 1

2 participants needed

1 Location

Brief description of study

WAIHA is caused by antibodies (proteins) that attach to red blood cells and causes their destruction. This causes anemia, which means the red blood cell count in the body becomes low. This medical research study is being done to find out more information about the investigational drug SYNT001 for the treatment of WAIHA to find out how well it works and if there are any side effects.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: ['Anemia, Hemolytic, Autoimmune']
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 827809

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 1b Multicenter Open-Label Safety Tolerability and Activity Study of SYNT001 in Subjects with Chronic Stable Warm Autoimmune Hemolytic Anemia (WAIHA)

Brief description of study

Eligibility of study

Find a site

Interested in the study